Peanut allergy

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

Retrieved on: 
Tuesday, February 20, 2024
PEOPLE, BAT, DBV Technologies, AAAAI, Immunotherapy, Safety, EST, Peanut allergy, Toddler, FIT, Longitudinal, Convention center, D.C, Associate, Walter, Patient, Clinical trial, Pediatrics, Asthma, Food, Diagnosis, DBV, Ageing, American Academy, Pharmaceutical industry

DBV is sponsoring a non-CME Product Theater titled “Importance of Early Intervention for Peanut Allergy.” Professors Hugh Sampson, M.D.

Key Points: 
  • DBV is sponsoring a non-CME Product Theater titled “Importance of Early Intervention for Peanut Allergy.” Professors Hugh Sampson, M.D.
  • DBV will host a booth (#567) in the AAAAI exhibit hall where attendees can learn more about epicutaneous immunotherapy with Viaskin, including our ongoing clinical trials in peanut-allergic children.
  • Chief Medical Officer at DBV Technologies.
  • “DBV, is committed to generating robust, long-term safety data with Viaskin Peanut to aid in future shared decision-making.

FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure

Retrieved on: 
Friday, February 16, 2024
Human services, Allergy, Fever, Division, Research, Food allergy, Polyp (medicine), Sinusitis, Hazelnut, Cosmetics, Multimedia, Hypersensitivity, Dietary supplement, Critical care, FDA, Food, Immunoglobulin E, Infection, Asthma, Anaphylaxis, Peanut allergy, Skin, Vomiting, Emergency, Vaccine, Risk, Animal, Safety, Heated tobacco product, Arthralgia, History, Milk, Malignancy, Rash, Public, Patient, Adrenaline, Peanut, Priority review

Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.

Key Points: 
  • Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.
  • "While it will not eliminate food allergies or allow patients to consume food allergens freely, its repeated use will help reduce the health impact if accidental exposure occurs."
  • Current treatment requires strict avoidance of the food(s) the patient is allergic to, and prompt administration of epinephrine to treat anaphylaxis should accidental exposures occur.
  • Xolair is the first FDA-approved medication to reduce allergic reactions to more than one type of food after accidental exposure.

ALK completes first part of phase 1 trial with peanut SLIT-tablet

Retrieved on: 
Thursday, January 18, 2024
Ageing, Development, Patient, Peanut allergy, Anaphylaxis, Quality of life, ALK, Disease, Safety, Research and development, Pharmaceutical industry

ALK to submit a protocol amendment for Phase 1-2 efficacy trial extension.

Key Points: 
  • ALK to submit a protocol amendment for Phase 1-2 efficacy trial extension.
  • ALK (ALKB:DC / OMX: ALK B / AKBLF) announced today that it has completed the first part of its phase 1 clinical trial (named ‘ALLIANCE’) for its investigational sublingual immunotherapy (‘SLIT’) tablet for the treatment of peanut allergy.
  • The first part of the trial investigated the safety and tolerability of 14 days treatment with the peanut tablet at different starting doses.
  • For further information please contact:
    This information is information that ALK is obliged to make public pursuant to the EU Market Abuse Regulation.

Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments

Retrieved on: 
Tuesday, January 16, 2024
Adrenaline, CMC, Patient, Therapy, Incidence, Peanut allergy, Chemistry, Partnership, CQD, Food allergy, SGI, Allergy, Quality of life, MCRI, Venture capital, IND, Drug development, New Drug Application, Pharmaceutical industry

MELBOURNE, Jan 16, 2024 - (ACN Newswire) - Prota Therapeutics Pty Ltd (Prota), an Australian biotechnology company focused on the development of novel oral immunotherapy treatments that induce remission of allergy, today announced financing of US$21 million in equity and debt financing.

Key Points: 
  • MELBOURNE, Jan 16, 2024 - (ACN Newswire) - Prota Therapeutics Pty Ltd (Prota), an Australian biotechnology company focused on the development of novel oral immunotherapy treatments that induce remission of allergy, today announced financing of US$21 million in equity and debt financing.
  • The round, led by Singapore-based SPRIM Global Investments (SGI), will help the company prepare for a Phase 3 clinical investigation of the company's PRT120 oral therapy for peanut allergy.
  • "SPRIM brings valuable expertise, capabilities and an international investment network to Prota's technology and clinical program," said Prota Executive Chairman Kelly Constable.
  • "This partnership and funding will accelerate Prota's drug development plans and clinical trial program, and we look forward to this strategic collaboration as Prota moves toward its Phase 3 trial."

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer

Retrieved on: 
Monday, January 8, 2024
AMAG Pharmaceuticals, Vaccine, Hospital, Immunoglobulin A, Nephrology, Amgen, Biotechnology, AstraZeneca, Drug development, Allergy, IgA nephropathy, MAA, MedImmune, Darbepoetin alfa, Johns Hopkins University, NDA, Medical microbiology, California State University, Therapy, GSK, Stanford University Medical Center, Peanut allergy, Regulatory affairs, Kidney, SVP, Patient, Hematology, Iron(II,III) oxide, Pharmaceutical industry

The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.

Key Points: 
  • The company has appointed Robert M. Brenner, M.D., as Chief Medical Officer to succeed Dr. Celia Lin, M.D.
  • ; and William D. Turner as Chief Development Officer, effective immediately.
  • Rob and Bill each have successfully guided multiple therapies through late clinical development, regulatory approval and commercial launch.
  • This is a key moment for Vera as we continue to advance the strategy for our late-stage clinical program,” said Marshall Fordyce, M.D., Chief Executive Officer of Vera Therapeutics.

Nine-month interim report (Q3) 2023

Retrieved on: 
Wednesday, November 15, 2023
HDM, Peanut allergy, Growth, AIT, BLA, House, Patient, Q3, EBIT, Ageing, ALK, Pharmaceutical industry

First interim readouts from the Phase 1 trial of the tablet treatment for peanut allergy are still expected end-2023.

Key Points: 
  • First interim readouts from the Phase 1 trial of the tablet treatment for peanut allergy are still expected end-2023.
  • Global tablet sales and SCIT/SLIT-drops sales are still expected to grow by double digits respectively in the second half of the year.
  • Additionally, we are excited about the positive results from the recent Phase 3 paediatric studies, reinforcing our long-term growth prospects.
  • Being new to the company, I want to thank all employees for their warm welcome and for their dedicated efforts.”

Camallergy and OnDosis Announce a Groundbreaking Partnership to Revolutionize Food Allergy Treatment

Retrieved on: 
Wednesday, November 29, 2023
Managed Care, Hospitals, Pharmaceutical, Health, Immune system, US Foods, MHRA, Patient, Multimedia, Medicine, FDA, OIT, Food and Drug Administration, University, MD, Partnership, Peanut allergy, Health care, Food, Physician, Food allergy, Dose, Pharmaceutical industry, Vaccine

View the full release here: https://www.businesswire.com/news/home/20231129814223/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231129814223/en/
    This partnership is set to transform the way food allergies (including peanut allergy) are treated, combining Camallergy's innovative therapies with OnDosis' cutting-edge Dosage Manager device technology.
  • The drug-device combination aims to address the challenges physicians face in offering oral immunotherapy, making the treatment more accessible for patients.
  • The collaboration between Camallergy and OnDosis aims to dramatically reduce the treatment burden associated with traditional oral immunotherapy.
  • Sherden Timmins, CEO of Camallergy: "This partnership with OnDosis represents a pivotal moment in our mission to tackle food allergies.

Stallergenes Greer Announces Publication of Positive Results for PALFORZIA® Phase 3 Study in Peanut-allergic Children Aged 1 to 3 Years

Retrieved on: 
Monday, November 20, 2023
Research, Fitness & Nutrition, Clinical Trials, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Safety, Prevalence, Hope, Patient, Death, NHS foundation trust, Pediatric Allergy and Immunology, Peanut allergy, AIT, Geoffrey Guy, Evelina London Children's Hospital, Hospital, Pharmaceutical industry, Poseidon

Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announces the publication of results from the Phase 3 POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study in the New England Journal of Medicine Evidence.

Key Points: 
  • Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announces the publication of results from the Phase 3 POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study in the New England Journal of Medicine Evidence.
  • The study evaluated the efficacy and safety of PALFORZIA [defatted powder of Arachis hypogaea L., semen (peanuts)] in peanut-allergic children aged 1 to 3 years.
  • Overall, 84.7% of patients on PALFORZIA and 93.8% of patients on placebo completed the study.
  • The results, published in the New England Journal of Medicine Evidence, are truly promising and potentially life-changing for young patients.

IgGenix Publishes New Data Supporting Further Development of Allergen-Specific Therapeutics for the Treatment of Peanut Allergy

Retrieved on: 
Tuesday, November 14, 2023
SAN, Allergy, SEQ, Entrepreneurship, Ara, Journal, Immunoglobulin E, Sneeze, Therapy, Death, Antibody, Peanut allergy, Doctor of Philosophy, Immunoglobulin G, Peanut, Cell, Cough, Vaccine

These antibodies and the results from the cutting-edge research provide a foundation for the development of allergy-specific therapeutics.

Key Points: 
  • These antibodies and the results from the cutting-edge research provide a foundation for the development of allergy-specific therapeutics.
  • The publication found that in peanut allergy, our immune systems produce specific antibodies, termed IgE antibodies, which show a consistent pattern or 'convergent evolution' across different individuals.
  • "Adults and children who experience severe peanut allergy deserve a safe, fast-acting and effective allergen-specific treatment option, which we are excited to be pioneering at IgGenix."
  • IgGenix's lead candidate in peanut allergy is set to enter Phase 1 human clinical trials in 2024.

Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment of Peanut Allergy

Retrieved on: 
Thursday, November 9, 2023
Anaphylaxis, Oral food challenge, American College, OMEGA, Clinical trial, ACAAI, MD, Food, Asthma, American College of Allergy, Asthma and Immunology, Safety, Therapy, Patient, Chronic pain, Peanut allergy, Nursing, Pharmaceutical industry

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, will present top-line results of the Phase 1 OMEGA (Oral Mucosal Escalation Goal Assessment) clinical trial during a late-breaking oral presentation at this year’s American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting in Anaheim, California. The data demonstrates that INT301, an innovative specially formulated toothpaste, can safely be used to deliver Oral Mucosal Immunotherapy (OMIT). The presentation is scheduled for Saturday, November 11 from 9:50 - 10:00 A.M. PST.

Key Points: 
  • The data demonstrates that INT301, an innovative specially formulated toothpaste, can safely be used to deliver Oral Mucosal Immunotherapy (OMIT).
  • The Phase 1 OMEGA Clinical Trial was a 48-week, double-blind, placebo-controlled trial involving 32 adult patients with peanut allergy to assess the safety of INT301.
  • INT301 represents a new approach to peanut desensitization in a fully functioning toothpaste that can easily be incorporated into a patient’s daily toothbrushing routine.
  • These results support further investigation of INT301 for the treatment of peanut allergy.